Article
Immunology
Charlotte Chene, Mohamed Maxime Jeljeli, Dominique Rongvaux-Gaida, Marine Thomas, Francois Rieger, Frederic Batteux, Carole Nicco
Summary: This study aimed to enhance the clearance of activated immune cells by combining arsenic trioxide (ATO) with a divalent cation to generate a Fenton reaction. In vitro experiments showed that the combination of ATO and copper chloride induced high levels of oxidative stress. In vivo experiments using a mouse model of GvHD demonstrated that the co-treatment effectively reduced lymphocyte activation and fibrosis, suggesting a potential treatment for GvHD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Ophthalmology
Fan Yang, Isami Hayashi, Shinri Sato, Yumiko Saijo-Ban, Mio Yamane, Masaki Fukui, Eisuke Shimizu, Jingliang He, Shinsuke Shibata, Shin Mukai, Kazuki Asai, Mamoru Ogawa, Yuqing Lan, Qingyan Zeng, Akito Hirakata, Kazuo Tsubota, Yoko Ogawa
Summary: The study revealed that sclerodermatous chronic graft-versus-host disease (cGVHD) can lead to pathological changes in blood vessels and meibomian glands (MGs) in the eyelids, including endothelial injury and activation, neovascularization, fibrotic changes, immune cell infiltration, and necrosis and apoptosis of MG basal cells.
Article
Dermatology
Akimasa Saito, Yuki Ichimura, Noriko Kubota, Ryota Tanaka, Yoshiyuki Nakamura, Yasuhiro Fujisawa, Rei Watanabe, Yosuke Ishitsuka, Manabu Fujimoto, Naoko Okiyama
Summary: In patients with GVHD, KCs in skin lesions of chronic GVHD show marked production of TGF beta 1, while IFN-gamma-deficient CD8 T-cell recipients have lower expression of TGF beta 1 in the epidermis. IFN-gamma promotes TGF beta 1 production by apoptotic KCs, mediating the development of widespread sclerodermatous changes in KC-targeting GVHD.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Article
Biophysics
Senthilnathan Palaniyandi, Ethan Strattan, Reena Kumari, Miranda Mysinger, Natalya Hakim, Melissa V. Kesler, Mutiah Apatira, Fabiola Bittencourt, Longcheng Wang, Zhaozhong Jia, Tarikere L. Gururaja, Ronald J. Hill, Gerhard C. Hildebrandt
Summary: Graft-versus-host disease (GVHD) is a major concern in allogeneic hematopoietic stem cell transplant. In this study, researchers found that selective inhibition of ITK was more effective than BTK inhibition in lengthening survival and reducing symptoms of chronic GVHD. These findings highlight the importance of developing ITK inhibitors for the treatment of GVHD.
BONE MARROW TRANSPLANTATION
(2023)
Article
Public, Environmental & Occupational Health
Majda Sahman, Snezana Mugosa, Nemanja Rancic
Summary: The utilization of immunosuppressive drugs is increasing in transplant patients in Montenegro and other observed countries. However, despite a decrease in the price per defined daily dose (DDD) for certain drugs, the overall cost of immunosuppressants is rising annually, which poses a significant financial burden on healthcare systems.
FRONTIERS IN PUBLIC HEALTH
(2021)
Article
Hematology
Yun Zhang, Lichong Shen, Katja Dreissigacker, Honglin Zhu, Thuong Trinh-Minh, Xianyi Meng, Cuong Tran-Manh, Clara Dees, Alexandru-Emil Matei, Chih-Wei Chen, Markus Ditschkowski, Stefan Krauss, Julia Winkler, Daniel Wolff, Mirjana Ziemer, Andreas Beilhack, Sigrid Karrer, Wolfgang Herr, Andreas Mackensen, Georg Schett, Bernd M. Spriewald, Joerg H. W. Distler
Summary: The inhibition of canonical WNT signaling plays an important role in the prevention and treatment of sclerodermatous cGVHD, with little impact on the graft-versus-leukemia effect. This treatment effectively prevents the development of clinical and histological features in sclGVHD models, suggesting potential translational applications due to the availability of clinically-used pyrvinium and ongoing clinical trials for tankyrase inhibitors.
Review
Oncology
Xiaoli Chen, Hengrui Sun, Kaniel Cassady, Shijie Yang, Ting Chen, Li Wang, Hongju Yan, Xi Zhang, Yimei Feng
Summary: Sirolimus is effective in reducing the incidence of grade II-IV acute GVHD but does not show significant improvement in chronic GVHD, overall survival, and relapse rate. However, it may increase the risk of thrombotic microangiopathy (TMA) and veno-occlusive disease (VOD) events.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
David E. Kandzari, Jacques J. Koolen, Gheorghe Doros, Hector M. Garcia-Garcia, Johan Bennett, Ariel Roguin, Elie G. Gharib, Donald E. Cutlip, Ron Waksman
Summary: This study compared the late-term (5-year) clinical outcomes of ultra-thin strut bioresorbable polymer sirolimus-eluting stents (BP SES) with thin strut durable polymer everolimus-eluting stents (DP EES). The results showed that BP SES was associated with a lower occurrence of target vessel-related myocardial infarction and late/very late definite/probable stent thrombosis.
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Medicine, Research & Experimental
Zixin Zhang, Tong Qiu, Jiangyuan Zhou, Xue Gong, Kaiying Yang, Xuepeng Zhang, Yuru Lan, Congxia Yang, Zilong Zhou, Yi Ji
Summary: Sirolimus and everolimus may have potential impacts on the growth and development of children. Using zebrafish models, this study found that these drugs could affect indicators such as survival, hatching, body length, and movement, as well as the development of the nervous system, blood vessels, and the immune system.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Dermatology
Kitty Yuechuan Wu, Stephanie Kim, Violet Muhan Liu, Alexis Sabino, Kathryn Minkhorst, Arjang Yazdani, Eva A. Turley
Summary: Patients with graft-versus-host disease (GVHD) exhibit characteristic mucocutaneous manifestations, such as erosive erythema, with marked production of TGF(β1 in chronic GVHD skin lesions but not in acute GVHD. IFN-γ promotes the production of TGF(β1 by apoptotic keratinocytes, leading to widespread sclerodermatous changes in GVHD patients.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
Summary: In this study, the clinical response to ruxolitinib in patients with steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation was investigated, and its safety profile was evaluated during the treatment course. The majority of patients treated with ruxolitinib showed significant treatment responses with a relatively well-tolerated safety profile, with lung involvement and matched related donors being associated with less favorable treatment response.
Article
Cardiac & Cardiovascular Systems
Masato Nakamura, Kazushige Kadota, Yoshihisa Nakagawa, Kengo Tanabe, Yoshiaki Ito, Tetsuya Amano, Yuichiro Maekawa, Akihiko Takahashi, Nobuo Shiode, Yoritaka Otsuka, Tomohiro Kawasaki, Yutaka Hikichi, Junya Shite, Ken Kozuma, Raisuke Iijima, Yoshitaka Murakami
Summary: This randomized comparison study showed that ultrathin-strut drug-eluting stents were noninferior to thin-strut drug-eluting stents in terms of target lesion failure at 1 year, indicating that differences in strut thickness among DES have little impact on clinical outcomes when implanted with intravascular imaging guidance.
JACC-CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Surgery
Thomas J. Wert, Stephanie Heeney, Maddy Morrison
Summary: This study aimed to evaluate the concentration/dose ratio for conversion between two mTOR inhibitors in heart transplant patients. The results showed that conversion between the two agents improved tolerability and did not lead to significant changes in measured lab values.
CLINICAL TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
Sebastian Wolf, Verena S. Hoffmann, Florian Sommer, Matthias Schrempf, Mingming Li, Martin Ryll, Ulrich Wirth, Matthias Ilmer, Jens Werner, Joachim Andrassy
Summary: Based on network meta-analysis, ERL combined with CNI showed the strongest anti-CMV effect compared to regular CNI treatment (RR 0.27, CI 0.22-0.32, p <0.0001).
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Benjamin Watkins, Kirsten M. Williams
Summary: Severe acute and chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after hematopoietic cell transplantation. Certain drugs can reduce the risk of GVHD, but they come with potential risks of relapse, graft failure, infections, and delayed immune reconstitution. However, these drugs have expanded donor options, especially for non-Caucasian individuals who previously had limited transplant options.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biophysics
Arnon Nagler, Frederic Baron, Myriam Labopin, Emmanuel Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria H. Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Mohamad Mohty
Summary: The survey revealed that detectable measurable residual disease (MRD) is a key prognostic factor in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Most centers assessed MRD using techniques such as PCR and flow cytometry, with assessments conducted every 2-3 months for up to 2 years post-transplant. This survey marks the first step towards including MRD status as a routine registry parameter for acute leukemia.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Klaus Hirschbuehl, Myriam Labopin, Mohamed Houhou, Ludovic Gabellier, Helene Labussiere-Wallet, Bruno Lioure, Dietrich Beelen, Jan Cornelissen, Gerald Wulf, Pavel Jindra, Herve Tilly, Jakob Passweg, Riita Niittyvuopio, Gesine Bug, Christoph Schmid, Arnon Nagler, Sebastian Giebel, Mohamad Mohty
Summary: The study evaluated the efficacy of second- and third-generation TKI in 140 patients with Ph + ALL, showing a response rate of 71% and an overall survival rate of 49% at 2 years and 33% at 5 years. TKI were found to be important compounds for managing active Ph + ALL post alloSCT, with comparable toxicity to pretransplant use.
BONE MARROW TRANSPLANTATION
(2021)
Review
Oncology
Christoph Schmid, Juergen Kuball, Gesine Bug
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Nutrition & Dietetics
R. Toenges, H. Greinix, A. Lawitschka, J. Halter, A. Baumgartner, A. Simon, J. Arends, P. Jaeger, M. Middeke, I. Hilgendorf, S. Klein, E. M. Wagner-Drouet, C. Schmid, G. Bug, D. Wolff
Summary: The study investigates the clinical practice of nutritional treatment after alloHSCT, revealing variability in nutritional approaches and indicating a need for more high-quality data to support evidence-based nutrition for patients.
CLINICAL NUTRITION
(2021)
Article
Hematology
Veronika Brixner, Gesine Bug, Petra Pohler, Doris Kraemer, Bernd Metzner, Andreas Voss, Jochen Casper, Ulrich Ritter, Stefan Klein, Nael Alakel, Rudolf Peceny, Hans G. Derigs, Frank Stegelmann, Martin Wolf, Hubert Schrezenmeier, Thomas Thiele, Erhard Seifried, Hans-Hermann Kapels, Andrea Doescher, Eduard K. Petershofen, Thomas H. Mueller, Axel Seltsam
Summary: The study indicates that transfusion of pathogen-reduced platelets produced with the UVC technology is safe, but non-inferiority was not demonstrated.
Article
Hematology
Anna Hecht, Julia A. Meyer, Johann-Christoph Jann, Katja Sockel, Aristoteles Giagounidis, Katharina S. Goetze, Anne Letsch, Detlef Haase, Richard F. Schlenk, Torsten Haferlach, Philippe Schafhausen, Gesine Bug, Michael Luebbert, Felicitas Thol, Guntram Buesche, Esther Schuler, Verena Nowak, Julia Oblaender, Stephanie Fey, Nadine Mueller, Georgia Metzgeroth, Wolf-Karsten Hofmann, Ulrich Germing, Florian Nolte, Mark Reinwald, Daniel Nowak
Summary: This study aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide in patients with myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q (MDS del5q). Results showed no significant effect of lenalidomide on DNA methylation status, and methylation patterns before treatment were not predictive of lenalidomide response. Some patients with hypermethylation of DNA sequences showed a trend towards inferior overall survival, suggesting the need to evaluate novel therapeutic targets.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, Research & Experimental
Eliza Wiercinska, Vera Schlipfenbacher, Gesine Bug, Peter Bader, Mareike Verbeek, Erhard Seifried, Halvard Bonig
Summary: Analysis of 100 pandemic-related allogeneic stem cell transplants collected from Europe showed that cryopreservation is feasible, with over 90% viability maintained. Although some CD34+ cells are lost during the process, the remaining stem cells ensure successful engraftment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Correction
Hematology
Esther Schuler, Eva-Maria Wagner-Drouet, Salem Ajib, Gesine Bug, Martina Crysandt, Sabine Dressler, Andreas Hausmann, Daniela Heidenreich, Klaus Hirschbuhl, Matthias Hoepting, Edgar Jost, Jennifer Kaivers, Stefan Klein, Michael Koldehoff, Lambros Kordelas, Oliver Kriege, Lutz P. Mueller, Christina Rautenberg, Judith Schaffrath, Christoph Schmid, Daniel Wolff, Rainer Haas, Martin Bornhaeuser, Thomas Schroeder, Guido Kobbe
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Nicolaus Kroeger, Katja Sockel, Christine Wolschke, Wolfgang Bethge, Richard F. Schlenk, Dominik Wolf, Michael Stadler, Guido Kobbe, Gerald Wulf, Gesine Bug, Kerstin Schaefer-Eckart, Christof Scheid, Florian Nolte, Jan Kroenke, Matthias Stelljes, Dietrich Beelen, Marion Heinzelmann, Detlef Haase, Hannes Buchner, Gabriele Bleckert, Aristoteles Giagounidis, Uwe Platzbecker
Summary: In older patients with MDS, reduced-intensity conditioning HSCT resulted in a significantly improved event-free survival compared to continuous 5-aza therapy. Bridging with 5-aza to HSCT before is associated with a considerable rate of dropouts due to disease progression, mortality, and adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Biophysics
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, Hendrik Veelken, Arne Brecht, Michael Stadler, Juergen Finke, Frederic Baron, Matthew Collin, Gesine Bug, Per Ljungman, Didier Blaise, Johanna Tischer, Adrian Bloor, Aleksander Kulagin, Sebastian Giebel, Norbert-Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed 318 acute leukemia patients who received DLI after alloSCT, showing that preemptive DLI was effective in reducing MRD and increasing chimerism, thus improving survival rates for patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Biophysics
Gesine Bug, Myriam Labopin, Riitta Niittyvuopio, Matthias Stelljes, Hans Christian Reinhardt, Inken Hilgendorf, Nicolaus Kroeger, Ain Kaare, Wolfgang Bethge, Kerstin Schaefer-Eckart, Mareike Verbeek, Stephan Mielke, Kristina Carlson, Ali Bazarbachi, Alexandros Spyridonidis, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: Retrospective analysis compared two different conditioning regimens for AML patients undergoing HSCT and found that using FluTBI resulted in lower relapse probability but higher non-relapse mortality. There were no significant differences in overall survival and GRFS between the two groups. Therefore, FluTBI may be more suitable for younger patients below the age of 55.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Dietrich W. Beelen, Renate Arnold, Matthias Stelljes, Nael Alakel, Arne Brecht, Gesine Bug, Donald Bunjes, Christoph Faul, Juergen Finke, Georg-Nikolaus Franke, Ernst Holler, Guido Kobbe, Nicolaus Kroeger, Wolf Roesler, Christof Scheid, Stefan Schoenland, Michael Stadler, Johanna Tischer, Eva Wagner-Drouet, Knut Wendelin, Monika Brueggemann, Lena Reiser, Dieter Hoelzer, Nicola Goekbuget
Summary: Allogeneic hematopoietic stem cell transplantation (HCT) is the standard treatment for adult high-risk acute lymphoblastic leukemia (ALL) and has contributed to improved outcomes. In this study, the analysis of a cohort of patients showed that age and minimal residual disease (MRD) were strong predictors of non-relapse mortality (NRM) and relapse, respectively. The use of adapted conditioning strategies can enhance the success of stem cell transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Meeting Abstract
Biophysics
Justin Loke, Myriam Labopin, Charles Craddock, Jan J. Cornelissen, Helene Labussiere-Wallet, Eva Maria Wagner-Drouet, Gwendolyn Van Gorkom, Nicolaas Schaap, Nicolaus Kroeger, Joan Hendrik Veelken, Montserrat Rovira, Herve Tilly, Hans Martin, Gesine Bug, Ali Bazarbachi, Sebastian Giebel, Eolia Brissot, Arnon Nagler, Jordi Esteve, Mohamad Mohty
BONE MARROW TRANSPLANTATION
(2021)
Meeting Abstract
Biophysics
Arnon Nagler, Myriam Labopin, Depei Wu, Goda Choi, Mahmoud Aljurf, Fabio Ciceri, Tobias Gedde-Dahl, Ellen Meijer, Riitta Niittyvuopio, Ivan Moiseev, Jean Henri Bourhis, Jan. J. Cornelissen, Gerard Socie, Yener Koc, Jonathan Canaani, Bipin Savani, Gesine Bug, Alexandros Spyridonidis, Sebastian Giebel, Eolia Brissot, Ali Bazarbachi, Jordi Esteve, Mohamd Mohty
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Roni Shouval, Joshua A. Fein, Myriam Labopin, Christina Cho, Ali Bazarbachi, Frederic Baron, Gesine Bug, Fabio Ciceri, Selim Corbacioglu, Jacques-Emmanuel Galimard, Sebastian Glebel, Maria H. Gilleece, Sergio Giralt, Ann Jakubowski, Silvia Montoto, Richard J. O'Reilly, Esperanza B. Papadopoulos, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Craig S. Sauter, Bipin N. Savani, Christoph Schmid, Alexandros Spyridonidis, Roni Tamari, Jurjen Versluis, Ibrahim Yakoub-Agha, Miguel Angel Perales, Mohamad Mohty, Arnon Nagler
Summary: The study developed a contemporary disease-risk stratification system that categorized patients into five risk groups based on histology and remission status. The system was able to predict overall survival after allogeneic hematopoietic stem-cell transplantation and may serve as a benchmark for future studies on heterogeneous cohorts.
LANCET HAEMATOLOGY
(2021)